Zobrazeno 1 - 4 of 4 pro vyhledávání: '"Maria Soledad Duran Nieto"'
2
Do chronic myeloid leukemia patients with late 'warning' responses benefit from 'watch and wait' or switching therapy to a second generation tyrosine kinase inhibitor?
Autor: Valentin, García-Gutiérrez, Jose Manuel, Puerta, Begoña, Maestro, Luis Felipe, Casado Montero, Alfonso, Muriel, Jose Ramon, Molina Hurtado, Manuel, Perez-Encinas, Maria Victoria, Moreno Romero, Pere Barba, Suñol, Ricardo, Sola Garcia, Raquel, De Paz, Maria Jose, Ramirez Sanchez, Santiago, Osorio, Maria Isabel, Mata Vazquez, Joaquin, Martinez López, Jose Luis, Sastre, Maria de Los Angles, Portero, Guiomar, Bautista, Maria Soledad, Duran Nieto, Pilar, Giraldo, Margarita, Jimenez Jambrina, Carmen, Burgaleta, Joaquin, Ruiz Aredondo, Maria Jesús, Peñarrubia, Maria José, Requena, María Del Carmen, Fernández Valle, Carmen, Calle, Antonio, Paz Coll, Jose Ángel, Hernández-Rivas, Rafael, Franco Osorio, Pilar, Cano, David, Tallón Pérez, Margarita, Fernández de la Mata, Pilar López, Garrido, Juan Luis, Steegmann
Publikováno v: American journal of hematology. 89(11)
In the latest recommendations for the management of chronic-phase chronic myeloid leukemia suboptimal responses have been reclassified as "warning responses." In contrast to previous recommendations current guidance advises close monitoring without c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6d96f97c8800af3efe0d9ee0c313e0c3
https://pubmed.ncbi.nlm.nih.gov/25059397
Zobrazit plný text záznamu
3
Impact of Age and Type of Underlying Disease on Long-Term Safety and Efficacy in Patients with Transfusional Hemosiderosis Treated with Deferasirox: Results from a 3-Year Non-Interventional Study (SENTINEL)
Autor: David Beneitez, Amin Azmon, Baba Inusa, Amal El-Beshlawy, Maria Soledad Duran Nieto, Blanca Xicoy, Mohsen Saleh Elalfy, Andreas Bruederle
Publikováno v: ResearcherID
Background: Hemosiderosis, due to frequent blood transfusions, is associated with liver, heart and endocrine dysfunction. Deferasirox (DFX), a once-daily oral iron chelator is used in the management of these patients (pts). The results of the 3-year
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f3153f5e5697d0ec6e363c0e6a010ea
https://doi.org/10.1182/blood.v128.22.4831.4831
Zobrazit plný text záznamu
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje